Grey market quotes the Mainboard at a ₹260 premium over the upper band of ₹988, pointing to an indicative listing near ₹1,248. Last updated: 29 Aug 2026, 22:15 IST.
| Date | GMP | Est. Gain |
|---|---|---|
| 29 Aug | +₹260 | +26.3% |
| 28 Aug | +₹270 | +27.3% |
Est. gain = GMP as % of the upper band price (indicative listing premium).
Grey Market Premium is an unofficial, off-exchange quote. SEBI does not recognise grey-market trading; the actual listing price is decided by order-book demand on debut day.
| Price Band | ₹938 - ₹988 |
|---|---|
| Lot Size | 15 shares |
| Issue Size | ₹1,757 Cr |
| Opening Date | 24 Aug 2026 |
| Closing Date | 27 Aug 2026 |
| Listing Date | 01 Sep 2026 |
| Subscription | 75.08x |
The latest unofficial grey market premium for Symbiotec Pharmalab IPO is ₹260 (+, as of 29 Aug 2026, 22:15 IST).
At the current GMP, shares are indicatively expected to list near ₹1,248 (upper band ₹988.0 plus ₹260 premium).
No. GMP is an unofficial sentiment indicator that can change quickly. The actual listing price is decided by regular order-book demand on the exchanges on debut day.
The full report with subscription status, RHP financials, strengths and data-based review signal is on the Symbiotec Pharmalab IPO detail page.
Read the full Symbiotec Pharmalab IPO report →
Last updated: 29 Aug 2026, 22:15 IST